By contrast, the TP53 mutation status and neoantigens did not reliably predict survival in the patients with SOC (Low CDI + TP53 mutation vs. Low CDI + wild-type TP53, P = 0.77; High CDI + TP53 mutation vs. High CDI + wild-type TP53, P = 0.250; Fig. 10E; Low CDI + Low neoantigen vs. Low CDI + High neoantigen, P = 0.713; High CDI + Low neoantigen vs. High CDI + High neoantigen, P = 0.405; Fig. 10F). This evidence concerns the gene UBXN11 and clostridium difficile infection.